BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 2010;61:317-28. [PMID: 20059340 DOI: 10.1146/annurev.med.080608.100623] [Cited by in Crossref: 160] [Cited by in F6Publishing: 151] [Article Influence: 13.3] [Reference Citation Analysis]
Number Citing Articles
1 Villanueva A, Forns X, Llovet JM. Molecular epidemiology in HCV-related hepatocellular carcinoma: first steps. J Hepatol. 2012;57:213-214. [PMID: 22282033 DOI: 10.1016/j.jhep.2012.01.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
2 Di Costanzo GG, de Stefano G, Tortora R, Farella N, Addario L, Lampasi F, Lanza AG, Cordone G, Imparato M, Caporaso N. Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma. Future Oncology 2015;11:943-51. [DOI: 10.2217/fon.14.291] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
3 Rodríguez-perálvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP, Burroughs AK. A Systematic Review of Microvascular Invasion in Hepatocellular Carcinoma: Diagnostic and Prognostic Variability. Ann Surg Oncol 2013;20:325-39. [DOI: 10.1245/s10434-012-2513-1] [Cited by in Crossref: 257] [Cited by in F6Publishing: 265] [Article Influence: 25.7] [Reference Citation Analysis]
4 Xu X, Zhou Y, Miao R, Chen W, Qu K, Pang Q, Liu C. Transcriptional modules related to hepatocellular carcinoma survival: coexpression network analysis. Front Med 2016;10:183-90. [DOI: 10.1007/s11684-016-0440-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
5 Beebe SJ. Hepatocellular carcinoma ablation and possible immunity in the age of nanosecond pulsed electric fields. J Hepatocell Carcinoma 2015;2:49-55. [PMID: 27508194 DOI: 10.2147/JHC.S83941] [Reference Citation Analysis]
6 Gao L, Morine Y, Yamada S, Saito Y, Ikemoto T, Tokuda K, Takasu C, Miyazaki K, Shimada M. Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells. PLoS One 2021;16:e0256755. [PMID: 34473785 DOI: 10.1371/journal.pone.0256755] [Reference Citation Analysis]
7 Yuan X, Sun X, Shi X, Jiang C, Yu D, Zhang W, Ding Y. USP39 regulates the growth of SMMC-7721 cells via FoxM1. Exp Ther Med 2017;13:1506-13. [PMID: 28413501 DOI: 10.3892/etm.2017.4115] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
8 Mohamed RA, Maghraby HM, Abd El Salam EM, Nageb HM, Ahmad EE, Mohamed NA. Evaluation of serum endoglin as noninvasive marker in hepatocellular carcinoma. Egypt J Intern Med 2015;27:15-20. [DOI: 10.4103/1110-7782.155832] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
9 Hafeez Bhatti AB, Dar FS, Waheed A, Shafique K, Sultan F, Shah NH. Hepatocellular Carcinoma in Pakistan: National Trends and Global Perspective. Gastroenterol Res Pract 2016;2016:5942306. [PMID: 26955390 DOI: 10.1155/2016/5942306] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
10 Mínguez B, Hoshida Y, Villanueva A, Toffanin S, Cabellos L, Thung S, Mandeli J, Sia D, April C, Fan JB, Lachenmayer A, Savic R, Roayaie S, Mazzaferro V, Bruix J, Schwartz M, Friedman SL, Llovet JM. Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol 2011;55:1325-31. [PMID: 21703203 DOI: 10.1016/j.jhep.2011.02.034] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 8.5] [Reference Citation Analysis]
11 Shi M, Chen MS, Sekar K, Tan CK, Ooi LL, Hui KM. A blood-based three-gene signature for the non-invasive detection of early human hepatocellular carcinoma. Eur J Cancer. 2014;50:928-936. [PMID: 24332572 DOI: 10.1016/j.ejca.2013.11.026] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
12 Shen YN, He HG, Shi Y, Cao J, Yuan JY, Wang ZC, Shi CF, Zhu N, Wei YP, Liu F, Huang JL, Yang GS, Lu JH. Krüppel-like factor 8 promotes cancer stem cell-like traits in hepatocellular carcinoma through Wnt/β-catenin signaling. Mol Carcinog 2017;56:751-60. [PMID: 27478926 DOI: 10.1002/mc.22532] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
13 Shaheen KY, Abdel-Mageed AI, Safwat E, AlBreedy AM. The value of serum midkine level in diagnosis of hepatocellular carcinoma. Int J Hepatol. 2015;2015:146389. [PMID: 25737783 DOI: 10.1155/2015/146389] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
14 Qi F, Inagaki Y, Gao B, Cui X, Xu H, Kokudo N, Li A, Tang W. Bufalin and cinobufagin induce apoptosis of human hepatocellular carcinoma cells via Fas- and mitochondria-mediated pathways. Cancer Sci. 2011;102:951-958. [PMID: 21288283 DOI: 10.1111/j.1349-7006.2011.01900.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 85] [Article Influence: 9.4] [Reference Citation Analysis]
15 Cornellà H, Alsinet C, Villanueva A. Molecular pathogenesis of hepatocellular carcinoma. Alcohol Clin Exp Res. 2011;35:821-825. [PMID: 21303380 DOI: 10.1111/j.1530-0277.2010.01406.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
16 Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C, Savic R, Cornella H, Llovet JM. New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res 2010;16:4688-94. [PMID: 20713493 DOI: 10.1158/1078-0432.CCR-09-1811] [Cited by in Crossref: 92] [Cited by in F6Publishing: 59] [Article Influence: 7.7] [Reference Citation Analysis]
17 da Costa AN, Plymoth A, Santos-Silva D, Ortiz-Cuaran S, Camey S, Guilloreau P, Sangrajrang S, Khuhaprema T, Mendy M, Lesi OA. Osteopontin and latent-TGF β binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma. Int J Cancer. 2015;136:172-181. [PMID: 24803312 DOI: 10.1002/ijc.28953] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
18 Huang X, Zhou L, Gong Z. Liver tumor models in transgenic zebrafish: an alternative in vivo approach to study hepatocarcinogenes. Future Oncol 2012;8:21-8. [PMID: 22149032 DOI: 10.2217/fon.11.137] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
19 Govaere O, Petz M, Wouters J, Vandewynckel YP, Scott EJ, Topal B, Nevens F, Verslype C, Anstee QM, Van Vlierberghe H, Mikulits W, Roskams T. The PDGFRα-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma. Oncogene 2017;36:6605-16. [PMID: 28783171 DOI: 10.1038/onc.2017.260] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
20 Govaere O, Roskams T. Pathogenesis and prognosis of hepatocellular carcinoma at the cellular and molecular levels. Clin Liver Dis. 2015;19:261-276. [PMID: 25921662 DOI: 10.1016/j.cld.2015.01.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
21 Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol 2015; 21(37): 10573-10583 [PMID: 26457017 DOI: 10.3748/wjg.v21.i37.10573] [Cited by in CrossRef: 188] [Cited by in F6Publishing: 182] [Article Influence: 26.9] [Reference Citation Analysis]
22 Wu XM, Xi ZF, Liao P, Huang HD, Huang XY, Wang C, Ma Y, Xia Q, Yao JG, Long XD. Diagnostic and prognostic potential of serum microRNA-4651 for patients with hepatocellular carcinoma related to aflatoxin B1. Oncotarget 2017;8:81235-49. [PMID: 29113383 DOI: 10.18632/oncotarget.16027] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
23 Zou K, Lu X, Ye K, Wang C, You T, Chen J. Krüppel-like factor 2 promotes cell proliferation in hepatocellular carcinoma through up-regulation of c-myc. Cancer Biol Ther 2016;17:20-6. [PMID: 26853883 DOI: 10.1080/15384047.2015.1108484] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
24 Li H, Miao Q, Xu CW, Huang JH, Zhou YF, Wu MJ. OTX1 Contributes to Hepatocellular Carcinoma Progression by Regulation of ERK/MAPK Pathway. J Korean Med Sci 2016;31:1215-23. [PMID: 27478331 DOI: 10.3346/jkms.2016.31.8.1215] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
25 Zhang H, Li G, Zhang Y, Shi J, Yan B, Tang H, Chen S, Zhang J, Wen P, Wang Z, Pang C, Li J, Guo W, Zhang S. Targeting BET Proteins With a PROTAC Molecule Elicits Potent Anticancer Activity in HCC Cells. Front Oncol 2019;9:1471. [PMID: 31993368 DOI: 10.3389/fonc.2019.01471] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 Schröder PC, Fernández-Irigoyen J, Bigaud E, Serna A, Renández-Alcoceba R, Lu SC, Mato JM, Prieto J, Corrales FJ. Proteomic analysis of human hepatoma cells expressing methionine adenosyltransferase I/III: Characterization of DDX3X as a target of S-adenosylmethionine. J Proteomics 2012;75:2855-68. [PMID: 22270009 DOI: 10.1016/j.jprot.2012.01.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
27 Wang J, Leng X, Wang G, Wan X, Cao H. The construction of intrahepatic cholangiocarcinoma model in zebrafish. Sci Rep 2017;7:13419. [PMID: 29042681 DOI: 10.1038/s41598-017-13815-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
28 Perra A, Kowalik MA, Ghiso E, Ledda-Columbano GM, Di Tommaso L, Angioni MM, Raschioni C, Testore E, Roncalli M, Giordano S, Columbano A. YAP activation is an early event and a potential therapeutic target in liver cancer development. J Hepatol. 2014;61:1088-1096. [PMID: 25010260 DOI: 10.1016/j.jhep.2014.06.033] [Cited by in Crossref: 134] [Cited by in F6Publishing: 134] [Article Influence: 16.8] [Reference Citation Analysis]
29 Sun H, Han B, Zhai H, Cheng X, Ma K. Significant association between MTHFR C677T polymorphism and hepatocellular carcinoma risk: a meta-analysis. Tumour Biol. 2014;35:189-193. [PMID: 24132589 DOI: 10.1007/s13277-013-1023-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
30 Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-26. [PMID: 21406195 DOI: 10.1053/j.gastro.2011.03.006] [Cited by in Crossref: 310] [Cited by in F6Publishing: 310] [Article Influence: 28.2] [Reference Citation Analysis]
31 Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics 2012;6:207-19. [PMID: 22904613 DOI: 10.2147/BTT.S23907] [Cited by in Crossref: 5] [Cited by in F6Publishing: 27] [Article Influence: 0.5] [Reference Citation Analysis]
32 Guarino M, Sessa A, Cossiga V, Morando F, Caporaso N, Morisco F, On behalf of the Special Interest Group on “Hepatocellular carcinoma and new anti-HCV therapies” of the Italian Association for the Study of the Liver. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows. World J Gastroenterol 2018; 24(24): 2582-2595 [PMID: 29962815 DOI: 10.3748/wjg.v24.i24.2582] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
33 Zheng Y, Gery S, Sun H, Shacham S, Kauffman M, Koeffler HP. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma. Cancer Chemother Pharmacol 2014;74:487-95. [PMID: 25030088 DOI: 10.1007/s00280-014-2495-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 5.1] [Reference Citation Analysis]
34 Jiang Y, Chen S, Jia S, Zhu Z, Gao X, Dong D, Gao Y. Association of HLA-G 3′ UTR 14-bp Insertion/Deletion Polymorphism with Hepatocellular Carcinoma Susceptibility in a Chinese Population. DNA and Cell Biology 2011;30:1027-32. [DOI: 10.1089/dna.2011.1238] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
35 Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, Hainaut P, Marrero JA, Beretta L. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012;55:483-90. [PMID: 21953299 DOI: 10.1002/hep.24703] [Cited by in Crossref: 185] [Cited by in F6Publishing: 184] [Article Influence: 16.8] [Reference Citation Analysis]
36 Szepeshazi K, Schally AV, Rick FG, Block NL, Vidaurre I, Halmos G, Szalontay L. Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II. Anticancer Drugs. 2012;23:906-913. [PMID: 22926257 DOI: 10.1097/cad.0b013e328354bd25] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
37 Heinz WJ, Kahle K, Helle-beyersdorf A, Schirmer D, Lenker U, Keller D, Langmann P, Klinker H. High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid. Cancer Chemother Pharmacol 2011;68:239-45. [DOI: 10.1007/s00280-010-1474-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
38 Marisi G, Cucchetti A, Ulivi P, Canale M, Cabibbo G, Solaini L, Foschi FG, De Matteis S, Ercolani G, Valgiusti M, Frassineti GL, Scartozzi M, Casadei Gardini A. Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? World J Gastroenterol 2018; 24(36): 4152-4163 [PMID: 30271080 DOI: 10.3748/wjg.v24.i36.4152] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 63] [Article Influence: 18.0] [Reference Citation Analysis]
39 Yu Z, Li Y, Han T, Liu Z. Demethylation of the HACE1 gene promoter inhibits the proliferation of human liver cancer cells. Oncol Lett 2019;17:4361-8. [PMID: 30988809 DOI: 10.3892/ol.2019.10139] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
40 Hu S, Tao R, Wang S, Wang C, Zhao X, Zhao H, Li L, Zhu S, He Y, Jiang X, Gao Y. MicroRNA-21 promotes cell proliferation in human hepatocellular carcinoma partly by targeting HEPN1. Tumor Biol 2015;36:5467-72. [DOI: 10.1007/s13277-015-3213-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
41 Tunissiolli NM, Castanhole-Nunes MMU, Biselli-Chicote PM, Pavarino EC, da Silva RF, da Silva RC, Goloni-Bertollo EM. Hepatocellular Carcinoma: a Comprehensive Review of Biomarkers, Clinical Aspects, and Therapy. Asian Pac J Cancer Prev. 2017;18:863-872. [PMID: 28545181 DOI: 10.22034/apjcp.2017.18.4.863] [Cited by in F6Publishing: 29] [Reference Citation Analysis]
42 Ao L, Zhang Z, Guan Q, Guo Y, Guo Y, Zhang J, Lv X, Huang H, Zhang H, Wang X, Guo Z. A qualitative signature for early diagnosis of hepatocellular carcinoma based on relative expression orderings. Liver Int 2018;38:1812-9. [PMID: 29682909 DOI: 10.1111/liv.13864] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
43 Xu Y, Ge K, Lu J, Huang J, Wei W, Huang Q. MicroRNA-493 suppresses hepatocellular carcinoma tumorigenesis through down-regulation of anthrax toxin receptor 1 (ANTXR1) and R-Spondin 2 (RSPO2). Biomed Pharmacother 2017;93:334-43. [PMID: 28651234 DOI: 10.1016/j.biopha.2017.06.047] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
44 Ezzoukhry Z, Louandre C, Trécherel E, Godin C, Chauffert B, Dupont S, Diouf M, Barbare JC, Mazière JC, Galmiche A. EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int J Cancer. 2012;131:2961-2969. [PMID: 22514082 DOI: 10.1002/ijc.27604] [Cited by in Crossref: 86] [Cited by in F6Publishing: 83] [Article Influence: 8.6] [Reference Citation Analysis]
45 Rafiullah, Ali A, Mohiuddin H, Zahid U, Abushahin L. Innovations in the Management of Hepatocellular Carcinoma. American Journal of Therapeutics 2018;25:e362-8. [DOI: 10.1097/mjt.0000000000000713] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 Qian Y, Wang JW, Fang Y, Yuan XD, Fan YC, Gao S, Wang K. Measurement of Cyclin D2 (CCND2) Gene Promoter Methylation in Plasma and Peripheral Blood Mononuclear Cells and Alpha-Fetoprotein Levels in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma. Med Sci Monit 2020;26:e927444. [PMID: 33320844 DOI: 10.12659/MSM.927444] [Reference Citation Analysis]
47 Abd-Elfatah G, Gad-Allah AN. RASSF1A, RECK genotypes and haplotypes in Egyptian population with Hepatocellular carcinoma. Immunol Lett 2016;173:36-41. [PMID: 26921475 DOI: 10.1016/j.imlet.2016.02.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
48 Wang S, Zhu Y, He H, Liu J, Xu L, Zhang H, Liu H, Liu W, Liu Y, Pan D, Chen L, Wu Q, Xu J, Gu J. Sorafenib suppresses growth and survival of hepatoma cells by accelerating degradation of enhancer of zeste homolog 2. Cancer Sci 2013;104:750-9. [PMID: 23421437 DOI: 10.1111/cas.12132] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
49 Ge K, Huang J, Wang W, Gu M, Dai X, Xu Y, Wu H, Li G, Lu H, Zhong J, Huang Q. Serine protease inhibitor kazal-type 6 inhibits tumorigenesis of human hepatocellular carcinoma cells via its extracellular action. Oncotarget 2017;8:5965-75. [PMID: 27999203 DOI: 10.18632/oncotarget.13983] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
50 Yu Q, Qian W, Wang J, Wu Y, Zhang J, Chen W. An indel polymorphism in the 3' untranslated region of JAK1 confers risk for hepatocellular carcinoma possibly by regulating JAK1 transcriptional activity in a Chinese population. Oncol Lett 2018;15:8088-94. [PMID: 29731916 DOI: 10.3892/ol.2018.8347] [Reference Citation Analysis]
51 Golob-Schwarzl N, Bettermann K, Mehta AK, Kessler SM, Unterluggauer J, Krassnig S, Kojima K, Chen X, Hoshida Y, Bardeesy NM, Müller H, Svendova V, Schimek MG, Diwoky C, Lipfert A, Mahajan V, Stumptner C, Thüringer A, Fröhlich LF, Stojakovic T, Nilsson KPR, Kolbe T, Rülicke T, Magin TM, Strnad P, Kiemer AK, Moriggl R, Haybaeck J. High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype. Transl Oncol 2019;12:256-68. [PMID: 30439626 DOI: 10.1016/j.tranon.2018.10.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
52 Filmus J, Capurro M. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma. FEBS J 2013;280:2471-6. [DOI: 10.1111/febs.12126] [Cited by in Crossref: 111] [Cited by in F6Publishing: 109] [Article Influence: 12.3] [Reference Citation Analysis]
53 Han SX, Zhu Q, Ma JL, Zhao J, Huang C, Jia X, Zhang D. Lowered HGK expression inhibits cell invasion and adhesion in hepatocellular carcinoma cell line HepG2. World J Gastroenterol 2010; 16(36): 4541-4548 [PMID: 20857524 DOI: 10.3748/wjg.v16.i36.4541] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
54 Zaini VA, Sugita P, Irfana L, Achmadi SS. In Silico Screening Anticancer of Six Triterpenoids toward miR-494 and TNF-α Targets. J Kim Sains Apl 2020;23:117-23. [DOI: 10.14710/jksa.23.4.117-123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Zhu G, Chen Y, Zhang X, Wu Q, Zhao Y, Chen Y, Sun F, Qiao Y, Wang J. 12-O-Tetradecanoylphorbol-13-acetate (TPA) is anti-tumorigenic in liver cancer cells via inhibiting YAP through AMOT. Sci Rep 2017;7:44940. [PMID: 28322318 DOI: 10.1038/srep44940] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
56 Zhang K, Rui X, Yan X. Curcumin Inhibits the Proliferation and Invasiveness of MHCC97-H Cells via p38 Signaling Pathway: Anti-Tumor Effect of Curcumin. Drug Dev Res 2014. [DOI: 10.1002/ddr.21210] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
57 Zhao H, Feng X, Han W, Diao Y, Han D, Tian X, Gao Y, Liu S, Zhu S, Yao C, Gu J, Sun C, Lei L. Enhanced binding to and killing of hepatocellular carcinoma cells in vitro by melittin when linked with a novel targeting peptide screened from phage display: ENHANCED BINDING TO AND KILLING OF HEPATOCELLULAR CARCINOMA CELLS. J Pept Sci 2013;19:639-50. [DOI: 10.1002/psc.2542] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
58 Li J, Chanrion M, Sawey E, Wang T, Chow E, Tward A, Su Y, Xue W, Lucito R, Zender L, Lowe SW, Bishop JM, Powers S. Reciprocal interaction of Wnt and RXR-α pathways in hepatocyte development and hepatocellular carcinoma. PLoS One 2015;10:e0118480. [PMID: 25738607 DOI: 10.1371/journal.pone.0118480] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
59 González Huezo MS, Sánchez Ávila JF. Consenso mexicano de diagnóstico y manejo del carcinoma hepatocelular. Revista de Gastroenterología de México 2014;79:250-62. [DOI: 10.1016/j.rgmx.2014.09.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
60 Sun J, Bie B, Zhang S, Yang J, Li Z. Long non-coding RNAs: critical players in hepatocellular carcinoma. Int J Mol Sci. 2014;15:20434-20448. [PMID: 25387074 DOI: 10.3390/ijms151120434] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 4.5] [Reference Citation Analysis]
61 Khalil A, Elgedawy J, Faramawi MF, Elfert A, Salama I, Abbass A, Elsaid H, Elsebaai H. Plasma Osteopontin Level as a Diagnostic Marker of Hepatocellular Carcinoma in Patients with Radiological Evidence of Focal Hepatic Lesions. Tumori 2013;99:100-7. [DOI: 10.1177/030089161309900117] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
62 Goh WW, Lee YH, Zubaidah RM, Jin J, Dong D, Lin Q, Chung MC, Wong L. Network-based pipeline for analyzing MS data: an application toward liver cancer. J Proteome Res 2011;10:2261-72. [PMID: 21410269 DOI: 10.1021/pr1010845] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
63 Liu XR, Cai CX, Luo LM, Zheng WL, Shi R, Zeng J, Xu YQ, Wei M, Ma WL. Decreased expression of Sushi Domain Containing 2 correlates to progressive features in patients with hepatocellular carcinoma. Cancer Cell Int 2016;16:15. [PMID: 26933386 DOI: 10.1186/s12935-016-0286-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
64 Yan Y, Yu J, Liu H, Guo S, Zhang Y, Ye Y, Xu L, Ming L. Construction of a long non-coding RNA-associated ceRNA network reveals potential prognostic lncRNA biomarkers in hepatocellular carcinoma. Pathology - Research and Practice 2018;214:2031-8. [DOI: 10.1016/j.prp.2018.09.022] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
65 Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63:844-855. [PMID: 24531850 DOI: 10.1136/gutjnl-2013-306627] [Cited by in Crossref: 790] [Cited by in F6Publishing: 814] [Article Influence: 98.8] [Reference Citation Analysis]
66 Augello C, Vaira V, Caruso L, Destro A, Maggioni M, Park YN, Montorsi M, Santambrogio R, Roncalli M, Bosari S. MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma. Liver Int. 2012;32:772-782. [PMID: 22429613 DOI: 10.1111/j.1478-3231.2012.02795.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 72] [Article Influence: 6.5] [Reference Citation Analysis]
67 Malz M, Pinna F, Schirmacher P, Breuhahn K. Transcriptional regulators in hepatocarcinogenesis--key integrators of malignant transformation. J Hepatol 2012;57:186-95. [PMID: 22446689 DOI: 10.1016/j.jhep.2011.11.029] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
68 Urtasun R, Latasa MU, Demartis MI, Balzani S, Goñi S, Garcia-Irigoyen O, Elizalde M, Azcona M, Pascale RM, Feo F, Bioulac-Sage P, Balabaud C, Muntané J, Prieto J, Berasain C, Avila MA. Connective tissue growth factor autocriny in human hepatocellular carcinoma: oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation. Hepatology 2011;54:2149-58. [PMID: 21800344 DOI: 10.1002/hep.24587] [Cited by in Crossref: 90] [Cited by in F6Publishing: 82] [Article Influence: 9.0] [Reference Citation Analysis]
69 Shi Z, Luo Y, Zhu M, Zhou Y, Zheng B, Wu D, Wang S, Xie X, Lin H, Yu X. Expression Analysis of Long Non-Coding RNA HAR1A and HAR1B in HBV-Induced Hepatocullular Carcinoma in Chinese Patients. Lab Med 2019;50:150-7. [PMID: 30304523 DOI: 10.1093/labmed/lmy055] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
70 Zhang T, Cao C, Wu D, Liu L. SNHG3 correlates with malignant status and poor prognosis in hepatocellular carcinoma. Tumor Biol 2016;37:2379-85. [DOI: 10.1007/s13277-015-4052-4] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 7.0] [Reference Citation Analysis]
71 Tian Y, Wong VW, Chan HL, Cheng AS. Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. Semin Cancer Biol. 2013;23:471-482. [PMID: 24018165 DOI: 10.1016/j.semcancer.2013.08.010] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 5.7] [Reference Citation Analysis]
72 Niederau C. Chronic hepatitis B in 2014: Great therapeutic progress, large diagnostic deficit. World J Gastroenterol 2014; 20(33): 11595-11617 [PMID: 25206267 DOI: 10.3748/wjg.v20.i33.11595] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
73 Morgan TA, Maturen KE, Dahiya N, Sun MRM, Kamaya A; American College of Radiology Ultrasound Liver Imaging and Reporting Data System (US LI-RADS) Working Group. US LI-RADS: ultrasound liver imaging reporting and data system for screening and surveillance of hepatocellular carcinoma. Abdom Radiol 2018;43:41-55. [DOI: 10.1007/s00261-017-1317-y] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 8.4] [Reference Citation Analysis]
74 Huang TS, Shyu YC, Turner R, Chen HY, Chen PJ. Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol. Syst Rev. 2013;2:37. [PMID: 23738605 DOI: 10.1186/2046-4053-2-37] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
75 Yan Q, Tang Y, He F, Xue J, Zhou R, Zhang X, Luo H, Zhou D, Wang X. Global analysis of DNA methylation in hepatocellular carcinoma via a whole-genome bisulfite sequencing approach. Genomics 2021;113:3618-34. [PMID: 34461228 DOI: 10.1016/j.ygeno.2021.08.024] [Reference Citation Analysis]
76 Dong H, Xiang S, Liang H, Li C, Zhang Z, Chen X. The niche of hepatic cancer stem cell and cancer recurrence. Medical Hypotheses 2013;80:666-8. [DOI: 10.1016/j.mehy.2013.01.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
77 Mohsen AM, Asfour MH, Salama AAA. Improved hepatoprotective activity of silymarin via encapsulation in the novel vesicular nanosystem bilosomes. Drug Development and Industrial Pharmacy 2017;43:2043-54. [DOI: 10.1080/03639045.2017.1361968] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
78 Yildiz G, Arslan-Ergul A, Bagislar S, Konu O, Yuzugullu H, Gursoy-Yuzugullu O, Ozturk N, Ozen C, Ozdag H, Erdal E. Genome-wide transcriptional reorganization associated with senescence-to-immortality switch during human hepatocellular carcinogenesis. PLoS One. 2013;8:e64016. [PMID: 23691139 DOI: 10.1371/journal.pone.0064016] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
79 Petrini I, Lencioni M, Ricasoli M, Iannopollo M, Orlandini C, Oliveri F, Bartolozzi C, Ricci S. Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2012;69:773-780. [PMID: 22033636 DOI: 10.1007/s00280-011-1753-2] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.5] [Reference Citation Analysis]
80 Cruz CR, Carvalho ARMR, Maranhão ACN, Aroucha DB, Foinquinos GA, Carvalho SRC, Vasconcelos LRS, Pereira LMMB. Clinical and laboratory parameters associated with li-rads as diagnostic of liver nodule in patients with cirrhosis. Transl Gastroenterol Hepatol 2021;6:55. [PMID: 34805577 DOI: 10.21037/tgh.2020.01.05] [Reference Citation Analysis]
81 Dietrich CF, Teufel A, Sirlin CB, Dong Y. Surveillance of hepatocellular carcinoma by medical imaging. Quant Imaging Med Surg 2019;9:1904-10. [PMID: 31867241 DOI: 10.21037/qims.2019.10.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
82 Zhu X, Wu X, Cheng J, Liao H, Di X, Li L, Li R, Zhou Y, Zhang X. Dalbinol, a rotenoid from Amorpha fruticosa L., exerts anti-proliferative activity by facilitating β-catenin degradation in hepatocellular carcinoma cells. Oncotarget 2017;8:47755-66. [PMID: 28548956 DOI: 10.18632/oncotarget.17766] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
83 Maurya AK, Vinayak M. Anticarcinogenic action of quercetin by downregulation of phosphatidylinositol 3-kinase (PI3K) and protein kinase C (PKC) via induction of p53 in hepatocellular carcinoma (HepG2) cell line. Mol Biol Rep 2015;42:1419-29. [DOI: 10.1007/s11033-015-3921-7] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 8.9] [Reference Citation Analysis]
84 Della Corte C, Colombo M. Surveillance for hepatocellular carcinoma. Semin Oncol. 2012;39:384-398. [PMID: 22846857 DOI: 10.1053/j.seminoncol.2012.05.002] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
85 Wang S, Huang X, Li Y, Lao H, Zhang Y, Dong H, Xu W, Li JL, Li M. RN181 suppresses hepatocellular carcinoma growth by inhibition of the ERK/MAPK pathway. Hepatology 2011;53:1932-42. [PMID: 21391225 DOI: 10.1002/hep.24291] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
86 Suresh M, Menne S. Application of the woodchuck animal model for the treatment of hepatitis B virus-induced liver cancer. World J Gastrointest Oncol 2021; 13(6): 509-535 [PMID: 34163570 DOI: 10.4251/wjgo.v13.i6.509] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
87 Pedica F, Ruzzenente A, Bagante F, Capelli P, Cataldo I, Pedron S, Iacono C, Chilosi M, Scarpa A, Brunelli M. A re-emerging marker for prognosis in hepatocellular carcinoma: the add-value of fishing c-myc gene for early relapse. PLoS One. 2013;8:e68203. [PMID: 23874541 DOI: 10.1371/journal.pone.0068203] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
88 Colombo F, Baldan F, Mazzucchelli S, Martin-Padura I, Marighetti P, Cattaneo A, Foglieni B, Spreafico M, Guerneri S, Baccarin M. Evidence of distinct tumour-propagating cell populations with different properties in primary human hepatocellular carcinoma. PLoS One. 2011;6:e21369. [PMID: 21731718 DOI: 10.1371/journal.pone.0021369] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
89 Wang WZ, Li L, Liu MY, Jin XB, Mao JW, Pu QH, Meng MJ, Chen XG, Zhu JY. Curcumin induces FasL-related apoptosis through p38 activation in human hepatocellular carcinoma Huh7 cells. Life Sci. 2013;92:352-358. [PMID: 23352975 DOI: 10.1016/j.lfs.2013.01.013] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
90 Fernando J, Sancho P, Fernández-Rodriguez CM, Lledó JL, Caja L, Campbell JS, Fausto N, Fabregat I. Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli. J Cell Physiol 2012;227:1319-25. [PMID: 21604268 DOI: 10.1002/jcp.22843] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 5.4] [Reference Citation Analysis]
91 Berasain C, Goñi S, Castillo J, Latasa MU, Prieto J, Ávila MA. Impairment of pre-mRNA splicing in liver disease: Mechanisms and consequences. World J Gastroenterol 2010; 16(25): 3091-3102 [PMID: 20593494 DOI: 10.3748/wjg.v16.i25.3091] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
92 Fong ZV, Tanabe KK. The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: A comprehensive and evidence-based comparison and review: Review of International HCC Guidelines. Cancer 2014;120:2824-38. [DOI: 10.1002/cncr.28730] [Cited by in Crossref: 153] [Cited by in F6Publishing: 153] [Article Influence: 19.1] [Reference Citation Analysis]
93 Bao H, Su H. Long Noncoding RNAs Act as Novel Biomarkers for Hepatocellular Carcinoma: Progress and Prospects. Biomed Res Int 2017;2017:6049480. [PMID: 28835896 DOI: 10.1155/2017/6049480] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
94 Nguyen AT, Emelyanov A, Koh CH, Spitsbergen JM, Lam SH, Mathavan S, Parinov S, Gong Z. A high level of liver-specific expression of oncogenic Kras(V12) drives robust liver tumorigenesis in transgenic zebrafish. Dis Model Mech. 2011;4:801-813. [PMID: 21729876 DOI: 10.1242/dmm.007831] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 6.0] [Reference Citation Analysis]
95 Marshall A, Alexander G. Vascular invasion leaves its mark in hepatocellular carcinoma. J Hepatol 2011;55:1174-5. [PMID: 21703166 DOI: 10.1016/j.jhep.2011.05.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
96 Kawada N. Evolution of hepatic fibrosis research. Hepatol Res. 2011;41:199-208. [PMID: 21338451 DOI: 10.1111/j.1872-034x.2011.00776.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
97 Schröder PC, Segura V, Riezu JI, Sangro B, Mato JM, Prieto J, Santamaría E, Corrales FJ. A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma. Funct Integr Genomics 2011;11:419-29. [PMID: 21562899 DOI: 10.1007/s10142-011-0230-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
98 Zhang J, Huang T, Zhang F, Xu J, Chen G, Wang X, Huang L, Peng Z. Prognostic role of serum carbohydrate antigen 19-9 levels in patients with resectable hepatocellular carcinoma. Tumour Biol 2015;36:2257-61. [PMID: 25787748 DOI: 10.1007/s13277-014-2435-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
99 Villanueva A, Newell P, Hoshida Y. Inherited hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2010;24:725-34. [PMID: 20955973 DOI: 10.1016/j.bpg.2010.07.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
100 European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943. [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001] [Cited by in Crossref: 3642] [Cited by in F6Publishing: 3517] [Article Influence: 364.2] [Reference Citation Analysis]
101 Li J, Liu K, Sheng Y, Zhang Q, Chen L, Qian H, Wu H, Su C. Enrichment and identification of differentially expressed genes in hepatocellular carcinoma stem-like cells. Oncol Lett 2020;20:299. [PMID: 33101493 DOI: 10.3892/ol.2020.12162] [Reference Citation Analysis]
102 Psyrri A, Arkadopoulos N, Vassilakopoulou M, Smyrniotis V, Dimitriadis G. Pathways and targets in hepatocellular carcinoma. Expert Review of Anticancer Therapy 2014;12:1347-57. [DOI: 10.1586/era.12.113] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 5.5] [Reference Citation Analysis]
103 Heuman DM, Gilles HS, Solomon C, Bajaj JS. Should a radiological diagnosis of hepatocellular carcinoma be routinely confirmed by a biopsy? No. Eur J Intern Med. 2012;23:37-39. [PMID: 22153529 DOI: 10.1016/j.ejim.2011.09.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
104 Glantzounis GK, Karampa A, Peristeri DV, Pappas-Gogos G, Tepelenis K, Tzimas P, Cyrochristos DJ. Recent advances in the surgical management of hepatocellular carcinoma. Ann Gastroenterol 2021;34:453-65. [PMID: 34276183 DOI: 10.20524/aog.2021.0632] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Hamed O, Kimchi ET, Sehmbey M, Gusani NJ, Kaifi JT, Staveley-O’Carroll K. Impact of genetic targets on cancer therapy: hepatocellular cancer. Adv Exp Med Biol. 2013;779:67-90. [PMID: 23288636 DOI: 10.1007/978-1-4614-6176-0_4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
106 Yang XX, Sun JZ, Li FX, Wu YS, Du HY, Zhu W, Li XH, Li M. Aberrant methylation and downregulation of sall3 in human hepatocellular carcinoma. World J Gastroenterol 2012; 18(21): 2719-2726 [PMID: 22690083 DOI: 10.3748/wjg.v18.i21.2719] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
107 Xiang X, Deng L, Xiong R, Xiao D, Chen Z, Yang F, Liu K, Feng G. Tex10 is upregulated and promotes cancer stem cell properties and chemoresistance in hepatocellular carcinoma. Cell Cycle 2018;17:1310-8. [PMID: 30045663 DOI: 10.1080/15384101.2018.1480208] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
108 Avruch J, Zhou D, Fitamant J, Bardeesy N. Mst1/2 signalling to Yap: gatekeeper for liver size and tumour development. Br J Cancer. 2011;104:24-32. [PMID: 21102585 DOI: 10.1038/sj.bjc.6606011] [Cited by in Crossref: 78] [Cited by in F6Publishing: 77] [Article Influence: 6.5] [Reference Citation Analysis]
109 Pogribny IP, Rusyn I. Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett. 2014;342:223-230. [PMID: 22306342 DOI: 10.1016/j.canlet.2012.01.038] [Cited by in Crossref: 109] [Cited by in F6Publishing: 114] [Article Influence: 10.9] [Reference Citation Analysis]
110 Xie QL, Liu Y, Zhu Y. Chromosome region maintenance 1 expression and its association with clinical pathological features in primary carcinoma of the liver. Exp Ther Med 2016;12:59-68. [PMID: 27347018 DOI: 10.3892/etm.2016.3283] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
111 Goh WW, Lee YH, Ramdzan ZM, Chung MC, Wong L, Sergot MJ. A network-based maximum link approach towards MS identifies potentially important roles for undetected ARRB1/2 and ACTB in liver cancer progression. Int J Bioinform Res Appl 2012;8:155-70. [PMID: 22961449 DOI: 10.1504/IJBRA.2012.048967] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
112 Yu SJ. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. Clin Mol Hepatol. 2016;22:7-17. [PMID: 27044761 DOI: 10.3350/cmh.2016.22.1.7] [Cited by in Crossref: 167] [Cited by in F6Publishing: 164] [Article Influence: 27.8] [Reference Citation Analysis]
113 Tian X, Ma P, Sui C, Li Y, Fu L, Jiang T, Wang Y, Jiang Y. Comprehensive assessment of the association between tumor necrosis factor alpha G238A polymorphism and liver cancer risk. Tumour Biol 2014;35:103-9. [PMID: 23943369 DOI: 10.1007/s13277-013-1012-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
114 Yang HD, Eun JW, Lee KB, Shen Q, Kim HS, Kim SY, Seo DW, Park WS, Lee JY, Nam SW. T-cell immune regulator 1 enhances metastasis in hepatocellular carcinoma. Exp Mol Med 2018;50:e420. [PMID: 29303507 DOI: 10.1038/emm.2017.166] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
115 Xu Y, Huang J, Ma L, Shan J, Shen J, Yang Z, Liu L, Luo Y, Yao C, Qian C. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. Cancer Lett. 2016;371:171-181. [PMID: 26655273 DOI: 10.1016/j.canlet.2015.11.034] [Cited by in Crossref: 89] [Cited by in F6Publishing: 95] [Article Influence: 12.7] [Reference Citation Analysis]
116 Mah WC, Lee CG. DNA methylation: potential biomarker in Hepatocellular Carcinoma. Biomark Res. 2014;2:5. [PMID: 24635883 DOI: 10.1186/2050-7771-2-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
117 Llovet JM, Paradis V, Kudo M, Zucman-Rossi J. Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma. Liver Transpl. 2011;17 Suppl 2:S67-S71. [PMID: 21594967 DOI: 10.1002/lt.22340] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
118 Huang P, Liu C, Li B, Zheng Y, Zou R, Huang J, Hu Z, Yuan Y. Preoperative mean corpuscular hemoglobin affecting long-term outcomes of hepatectomized patients with hepatocellular carcinoma. Mol Clin Oncol 2016;4:229-36. [PMID: 26893867 DOI: 10.3892/mco.2015.705] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
119 Kwon JH, Lee N, Park JY, Yu YS, Kim JP, Shin JH, Kim DS, Joh JW, Kim DS, Choi KY, Kang KJ, Kim G, Moon YH, Wang HJ. Actionable gene expression-based patient stratification for molecular targeted therapy in hepatocellular carcinoma. PLoS One 2013;8:e64260. [PMID: 23785399 DOI: 10.1371/journal.pone.0064260] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
120 Ding M, Li J, Yu Y, Liu H, Yan Z, Wang J, Qian Q. Integrated analysis of miRNA, gene, and pathway regulatory networks in hepatic cancer stem cells. J Transl Med 2015;13:259. [PMID: 26259570 DOI: 10.1186/s12967-015-0609-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
121 European Association for Study of Liver. European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599-641. [PMID: 22424278 DOI: 10.1016/j.ejca.2011.12.021] [Cited by in Crossref: 273] [Cited by in F6Publishing: 269] [Article Influence: 27.3] [Reference Citation Analysis]
122 Santambrogio R, Costa M, Strada D, Bertolini E, Zuin M, Barabino M, Opocher E. Intraoperative ultrasound score to predict recurrent hepatocellular carcinoma after radical treatments. Ultrasound Med Biol. 2011;37:7-15. [PMID: 21084155 DOI: 10.1016/j.ultrasmedbio.2010.10.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
123 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1974] [Article Influence: 530.5] [Reference Citation Analysis]
124 An J, Liu J, Liu L, Liu Y, Pan Y, Huang M, Qi F, Wen J, Xie K, Ma H, Shen H, Hu Z. A genetic variant in primary miR-378 is associated with risk and prognosis of hepatocellular carcinoma in a Chinese population. PLoS One 2014;9:e93707. [PMID: 24751683 DOI: 10.1371/journal.pone.0093707] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
125 Ding X, Cheng X, Gong M, Chen X, Yin F, Lai K. Hypermethylation and Expression Silencing of PDCD4 Gene in Hepatocellular Carcinoma: A Consort Study. Medicine (Baltimore) 2016;95:e2729. [PMID: 26871813 DOI: 10.1097/MD.0000000000002729] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
126 Ko SE, Lee MW, Lim HK, Min JH, Cha DI, Kang TW, Song KD, Kim MJ, Rhim H. The semi-erect position for better visualization of subphrenic hepatocellular carcinoma during ultrasonography examinations. Ultrasonography 2021;40:274-80. [PMID: 32660205 DOI: 10.14366/usg.20059] [Reference Citation Analysis]
127 Zaydfudim V, Smoot RL, Clark CJ, Kendrick ML, Que FG, Farnell MB, Nagorney DM. Role of operative therapy in non-cirrhotic patients with metastatic hepatocellular carcinoma. J Gastrointest Surg 2012;16:1516-23. [PMID: 22644447 DOI: 10.1007/s11605-012-1918-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
128 Hu L, Ye H, Huang G, Luo F, Liu Y, Liu Y, Yang X, Shen J, Liu Q, Zhang J. Long noncoding RNA GAS5 suppresses the migration and invasion of hepatocellular carcinoma cells via miR-21. Tumour Biol. 2016;37:2691-2702. [PMID: 26404135 DOI: 10.1007/s13277-015-4111-x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 101] [Article Influence: 13.3] [Reference Citation Analysis]
129 Wu X, Yao X, Cao Q, Wu Z, Wang Z, Liu F, Shen L. Clinicopathological and prognostic significance of CDH1 hypermethylation in hepatocellular carcinoma: a meta-analysis. Cancer Manag Res 2019;11:857-64. [PMID: 30697077 DOI: 10.2147/CMAR.S179710] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
130 Shao P, Sun D, Wang L, Fan R, Gao Z. Deep sequencing and comprehensive expression analysis identifies several molecules potentially related to human poorly differentiated hepatocellular carcinoma. FEBS Open Bio 2017;7:1696-706. [PMID: 29123978 DOI: 10.1002/2211-5463.12310] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
131 Hiramine Y, Uto H, Imamura Y, Tabu K, Baba Y, Hiwaki T, Sho Y, Tahara K, Higashi H, Tamai T. Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study. Exp Ther Med. 2011;2:433-441. [PMID: 22977522 DOI: 10.3892/etm.2011.237] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
132 Guerrieri F, Belloni L, Pediconi N, Levrero M. Pathobiology of Hepatitis B Virus-Induced Carcinogenesis. In: Liaw Y, Zoulim F, editors. Hepatitis B Virus in Human Diseases. Cham: Springer International Publishing; 2016. pp. 95-121. [DOI: 10.1007/978-3-319-22330-8_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
133 Huang B, Zhang B, Liang B, Fang L, Ye X. Ultra-low level detection of hepatocellular carcinoma global methylation using a AuNP modified carbon fiber microelectrode. RSC Adv 2020;10:16277-83. [DOI: 10.1039/d0ra00905a] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
134 Chen KF, Chen HL, Tai WT, Feng WC, Hsu CH, Chen PJ, Cheng AL. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther. 2011;337:155-161. [PMID: 21205925 DOI: 10.1124/jpet.110.175786] [Cited by in Crossref: 198] [Cited by in F6Publishing: 202] [Article Influence: 18.0] [Reference Citation Analysis]
135 Zhang Y, Tang J, Zhou X, Zhu SL, Li LQ. Diagnostic accuracy of midkine for hepatocellular carcinoma: A meta-analysis. Mol Genet Genomic Med 2020;8:e1071. [PMID: 31777190 DOI: 10.1002/mgg3.1071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
136 Li Q, Gao Y, Jia Z, Mishra L, Guo K, Li Z, Le X, Wei D, Huang S, Xie K. Dysregulated Krüppel-like factor 4 and vitamin D receptor signaling contribute to progression of hepatocellular carcinoma. Gastroenterology. 2012;143:799-810.e1-e2. [PMID: 22677193 DOI: 10.1053/j.gastro.2012.05.043] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 4.8] [Reference Citation Analysis]
137 Mato JM, Martínez-Chantar ML, Lu SC. Systems biology for hepatologists. Hepatology 2014;60:736-43. [PMID: 24449428 DOI: 10.1002/hep.27023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
138 Ocsoy I, Gulbakan B, Shukoor MI, Xiong X, Chen T, Powell DH, Tan W. Aptamer-conjugated multifunctional nanoflowers as a platform for targeting, capture, and detection in laser desorption ionization mass spectrometry. ACS Nano 2013;7:417-27. [PMID: 23211039 DOI: 10.1021/nn304458m] [Cited by in Crossref: 75] [Cited by in F6Publishing: 69] [Article Influence: 7.5] [Reference Citation Analysis]
139 Blum HE. Individualized medicine 2010. J Cell Mol Med 2010;14:2257-63. [PMID: 20731747 DOI: 10.1111/j.1582-4934.2010.01155.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
140 Zhang J, Chen G, Zhang P, Zhang J, Li X, Gan D, Cao X, Han M, Du H, Ye Y. The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. PLoS One. 2020;15:e0228857. [PMID: 32053643 DOI: 10.1371/journal.pone.0228857] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 10.5] [Reference Citation Analysis]
141 Ma K, He Y, Zhang H, Fei Q, Niu D, Wang D, Ding X, Xu H, Chen X, Zhu J. DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression. J Biol Chem. 2012;287:5639-5649. [PMID: 22117060 DOI: 10.1074/jbc.m111.291229] [Cited by in Crossref: 82] [Cited by in F6Publishing: 59] [Article Influence: 7.5] [Reference Citation Analysis]
142 Huang G, Li S, Yang N, Zou Y, Zheng D, Xiao T. Recent progress in circular RNAs in human cancers. Cancer Lett 2017;404:8-18. [PMID: 28705773 DOI: 10.1016/j.canlet.2017.07.002] [Cited by in Crossref: 57] [Cited by in F6Publishing: 63] [Article Influence: 11.4] [Reference Citation Analysis]
143 Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, Kamel IR, Ghasebeh MA, Pawlik TM. Hepatocellular carcinoma: From diagnosis to treatment. Surg Oncol. 2016;25:74-85. [PMID: 27312032 DOI: 10.1016/j.suronc.2016.03.002] [Cited by in Crossref: 165] [Cited by in F6Publishing: 175] [Article Influence: 27.5] [Reference Citation Analysis]
144 Luo P, Wu S, Yu Y, Ming X, Li S, Zuo X, Tu J. Current Status and Perspective Biomarkers in AFP Negative HCC: Towards Screening for and Diagnosing Hepatocellular Carcinoma at an Earlier Stage. Pathol Oncol Res. 2020;26:599-603. [PMID: 30661224 DOI: 10.1007/s12253-019-00585-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
145 Huang P, Qiu J, You J, Hong J, Li B, Zhou K, Chen G, Yuan Y, Zou R. Expression and prognostic significance of CIP2A mRNA in hepatocellular carcinoma and nontumoral liver tissues. Biomarkers 2012;17:422-9. [PMID: 22537152 DOI: 10.3109/1354750X.2012.680608] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
146 Nguyen AT, Koh V, Spitsbergen JM, Gong Z. Development of a conditional liver tumor model by mifepristone-inducible Cre recombination to control oncogenic kras V12 expression in transgenic zebrafish. Sci Rep 2016;6:19559. [PMID: 26790949 DOI: 10.1038/srep19559] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
147 Qiu X, Hu B, Huang Y, Deng Y, Wang X, Zheng F. Hypermethylation of ACP1, BMP4, and TSPYL5 in Hepatocellular Carcinoma and Their Potential Clinical Significance. Dig Dis Sci 2016;61:149-57. [DOI: 10.1007/s10620-015-3878-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
148 Park SH, Bang CS, Kim DJ. Biomarkers in HCV Infection. Adv Clin Chem 2015;70:131-96. [PMID: 26231487 DOI: 10.1016/bs.acc.2015.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
149 Xu G, Xu WY, Xiao Y, Jin B, Du SD, Mao YL, Zhang ZT. The emerging roles of non-coding competing endogenous RNA in hepatocellular carcinoma. Cancer Cell Int 2020;20:496. [PMID: 33061848 DOI: 10.1186/s12935-020-01581-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
150 Yang T, Song B, Zhang J, Yang GS, Zhang H, Yu WF, Wu MC, Lu JH, Shen F. STK33 promotes hepatocellular carcinoma through binding to c-Myc. Gut 2016;65:124-33. [PMID: 25398772 DOI: 10.1136/gutjnl-2014-307545] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
151 Xiao J, Sun Q, Bei Y, Zhang L, Dimitrova-Shumkovska J, Lv D, Yang Y, Cao Y, Zhao Y, Song M, Song Y, Wang F, Yang C. Therapeutic inhibition of phospholipase D1 suppresses hepatocellular carcinoma. Clin Sci (Lond) 2016;130:1125-36. [PMID: 27129182 DOI: 10.1042/CS20160087] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
152 Lee JH, Friso S, Choi SW. Epigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutrition. Nutrients 2014;6:3303-25. [PMID: 25195642 DOI: 10.3390/nu6083303] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 8.5] [Reference Citation Analysis]
153 Fan SS, Liao CS, Cao YD, Xiao PL, Deng T, Luo RC, Duan HX. A low serum Tat-interacting protein 30 level is a diagnostic and prognostic biomarker for hepatocellular carcinoma. Oncol Lett 2017;13:4208-14. [PMID: 28599422 DOI: 10.3892/ol.2017.6024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
154 Guo HM, Li JS, Zhang JP, Li DY, Li HF. Significance of serum sCD25 level in diagnosis of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2014; 22(34): 5344-5349 [DOI: 10.11569/wcjd.v22.i34.5344] [Reference Citation Analysis]
155 Chen TA, Wang JL, Hung SW, Chu CL, Cheng YC, Liang SM. Recombinant VP1, an Akt inhibitor, suppresses progression of hepatocellular carcinoma by inducing apoptosis and modulation of CCL2 production. PLoS One. 2011;6:e23317. [PMID: 21826248 DOI: 10.1371/journal.pone.0023317] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
156 Wen N, Cai Y, Li F, Ye H, Tang W, Song P, Cheng N. The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update. Biosci Trends 2022. [PMID: 35197399 DOI: 10.5582/bst.2022.01061] [Reference Citation Analysis]